Updated
Reviewed
Apr. 07, 2021

Management of Medication Toxicity or Intolerance

Nephrotoxic Effects

Table 15i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
Table 15i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
   
   
   
   

 

References

  1. Aliyannissa A, Kuswiyanto RB, Setiabudi D, Nataprawira HM, Alam A, Sekarwana N. Correlation between CD4 count and glomerular filtration rate or urine protein:creatinine ratio in human immunodeficiency virus-infected children. Kidney Res Clin Pract. 2020;39(1):40-46. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32146732.
  2. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28(7):619-625. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19561425.
  3. Brunel V, Massy N, Malval B. Atazanavir urolithiasis without recent intake of atazanavir. Ann Biol Clin (Paris). 2019;77(4):459-460. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31418708.
  4. Bunupuradah T, Phupitakphol T, Sophonphan J, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai adolescents. Pediatr Infect Dis J. 2017. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28719505.
  5. de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68(8):1850-1856. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23599359.
  6. Ekulu PM, Nkoy AB, Betukumesu DK, et al. APOL1 risk genotypes are associated with early kidney damage in children in sub-saharan Africa. Kidney Int Rep. 2019;4(7):930-938. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31317115.
  7. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32-40. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22732469.
  8. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455-1465. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30932951.
  9. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24(4):525-534. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20139752.
  10. Lim Y, Lyall H, Foster C. Tenofovir-associated nephrotoxicity in children with perinatally acquired HIV infection: a single-centre cohort study. Clin Drug Investig. 2015;35(5):327-333. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25861908.
  11. Lin KY, Liao SH, Liu WC, et al. Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy. PLoS One. 2015;10(9):e0137660. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26360703.
  12. Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA. Is abnormal urine protein/osmolality ratio associated with abnormal renal function in patients receiving tenofovir disoproxil fumarate? PLoS One. 2016;11(2):e0149562. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26872144.
  13. Nachman SA, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009;163(2):164-171. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19188649.
  14. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One. 2013;8(10):e77268. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24130871.
  15. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495-500. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23249917.
  16. Purswani MU, Patel K, Winkler CA, et al. Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth With perinatal HIV infection. J Acquir Immune Defic Syndr. 2016;73(1):63-68. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27035887.
  17. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J. 2009;28(3):204-209. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19209091.
  18. Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. HIV Med. 2012;13(9):526-532. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22413854.
  19. Soares DS, Cavalcante MG, Ribeiro SM, et al. Acute kidney injury in HIV-infected children: comparison of patients according to the use of highly active antiretroviral therapy. J Pediatr (Rio J). 2016;92(6):631-637. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27542916.
  20. Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25(2):171-176. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21076275.

 

Management of Medication Toxicity or Intolerance

Nephrotoxic Effects

Table 15i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
Table 15i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects
   
   
   
   

 

Download Guidelines